Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.
Article
Biochemistry & Molecular Biology
Jerome H. Kim et al.
Summary: Following the announcement of COVID-19 vaccine efficacy in clinical trials, a comprehensive strategy is needed for global vaccination, including manufacturing, support, supply coordination, equitable distribution, and logistics. Additionally, addressing scientific questions to improve vaccine efficacy is crucial for ending the pandemic effectively and efficiently.
Article
Medicine, General & Internal
Ann R. Falsey et al.
Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Psychology, Biological
Thomas Hale et al.
Summary: The Oxford COVID-19 Government Response Tracker (OxCGRT) records data on 19 different government COVID-19 policy indicators for over 190 countries. Covering closure and containment, health and economics measures, it creates an evidence base for effective responses.
NATURE HUMAN BEHAVIOUR
(2021)
Review
Medicine, Research & Experimental
Luca Falzone et al.
Summary: The COVID-19 pandemic has accelerated the development of accurate diagnostic methods to limit the spread of infection, including rapid antigen and antibody tests, immunoenzymatic serological tests, and molecular tests based on RT-PCR. In addition to these traditional methods, new techniques such as isothermal nucleic acid amplification and CRISPR/Cas-based approaches are being researched for potential diagnostic use. This review provides guidance on the diagnostic strategies available for COVID-19 diagnosis, describing the technical characteristics of the methods and discussing sample types, testing modalities, and timing.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
(2021)
Article
Medicine, General & Internal
Eleftheria Vasileiou et al.
Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.
Article
Medicine, General & Internal
Eric J. Haas et al.
Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.
Editorial Material
Medicine, General & Internal
Chris Baraniuk
Summary: The country where covid-19 first emerged is leading the way in promoting a series of vaccines domestically and internationally. However, lack of transparency around the data leads to a fragmented picture.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Review
Public, Environmental & Occupational Health
Jamal Hisham Hashim et al.
Summary: The COVID-19 pandemic in Malaysia has caused over 100 deaths and two waves of cases, with the first wave seeing no fatalities and full recoveries, while the second wave was largely driven by the Sri Petaling Tabligh cluster. The country implemented a Movement Control Order to contain the spread of the virus, resulting in economic losses but also successful control of the outbreak. Vaccine development is seen as the best approach to achieving herd immunity against COVID-19.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Infectious Diseases
Clara Mazagatos et al.
Summary: The study found that the effectiveness of mRNA COVID-19 vaccines for elderly residents in long-term care facilities in Spain was estimated at 71%, 88%, and 97% against SARS-CoV-2 infections, COVID-19 hospitalizations, and deaths, respectively.
Editorial Material
Medicine, General & Internal
Philip R. Krause et al.
Article
Medicine, General & Internal
Mine Durusu Tanriover et al.
Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.
Article
Medicine, General & Internal
Alejandro Jara et al.
Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
H. M. El Sahly et al.
Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Otavio Ranzani et al.
Summary: The study evaluates the effectiveness of the CoronaVac vaccine in the elderly population aged >= 70 years in Sao Paulo state, Brazil during widespread circulation of the gamma variant. The vaccine was found to significantly reduce the risk of symptomatic covid-19, hospital admissions, and deaths after completion of the two-dose regimen, but the effectiveness decreases with age among the elderly population.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Biotechnology & Applied Microbiology
Kaoru Araki et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2016)
Article
Infectious Diseases
Cornelius Remschmidt et al.
BMC INFECTIOUS DISEASES
(2015)
Article
Multidisciplinary Sciences
Adam L. Cohen et al.
Article
Public, Environmental & Occupational Health
E Hak et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
(2002)
